For the quarter ending 2026-03-31, JANX made $3,733K in revenue. -$28,101K in net income. Net profit margin of -752.77%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-03-31 |
|---|---|---|---|---|
| Collaboration revenue | 3,733 | -20,000* | 10,000 | - |
| Research and development | 26,813 | 21,369* | 34,629 | 25,055 |
| General and administrative | 11,133 | 11,075* | 10,622 | 9,842 |
| Total operating expenses | 37,946 | 32,444* | 45,251 | 34,897 |
| Loss from operations | -34,213 | -52,444* | -35,251 | -34,897 |
| Interest income | 9,852 | 10,552 | 10,938 | 11,389 |
| Total other income | 9,852 | 10,552* | 10,938 | 11,389 |
| Net loss | -24,361 | -41,893* | -24,313 | -23,508 |
| Unrealized loss on available-for-sale securities, net | -3,740 | -1,459* | 815 | 1,593 |
| Comprehensive loss | -28,101 | -43,352 | -23,498 | -21,915 |
| Basic EPS | -0.39 | -0.698 | -0.39 | -0.38 |
| Diluted EPS | -0.39 | -0.698 | -0.39 | -0.38 |
| Basic Average Shares | 62,665,717 | 62,085,591 | 62,023,685 | 61,791,721 |
| Diluted Average Shares | 62,665,717 | 62,085,591 | 62,023,685 | 61,791,721 |
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)